Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06667272 · 1 trial · 1 indication
Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.
| Arm | Type | Description |
|---|---|---|
| Cohort 1_Period 1_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 1_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 1_Period 2_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 2_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 1_Period 3_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 3_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohrot 1_Period 4_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 1_Period 4_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 1_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 1_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 2_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 2_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 3_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 3_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Cohort 2_Period 4_Active | EXPERIMENTAL | Single ascending dose of PF-06667272 |
| Cohort 2_Period 4_Placebo | PLACEBO_COMPARATOR | Single dose of placebo |
| Name | Type | Description |
|---|---|---|
| PF-06667272 | DRUG | Single ascending dose of PF-06667272 |
| Placebo | OTHER | Single dose of placebo |
Inclusion Criteria: * Healthy males and female of non-childbearing potential; * Body Mass Index 17.5-30.5 kg/m2; * Body weight \>50 kg; Exclusion Criteria: * Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychi...
PF-06667272 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other.
PF-06667272 is being studied for use in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any medical condition and is still in the early stages of clinical testing.
PF-06667272 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate this investigational small molecule in healthy volunteers.
PF-06667272 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers as part of early-stage clinical trials.
PF-06667272 has one completed Phase 1 clinical trial, identified as NCT03126149, titled "First in Human Study for PF-06667272." This trial enrolled 16 healthy volunteers in Belgium and was a randomized, double-blind, placebo-controlled study.
PF-06667272 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, but it has not completed the clinical trials necessary for regulatory approval.